ASCO GU 2022

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Trends Analysis

Mar 18, 2022

Exploring the Metastatic Castration-Sensitive Prostate Cancer Market Landscape

ASCO GU 2022 - Urothelial Carcinoma

Mar 03, 2022

Data readout of potential ADCs: Enhertu gears up for Urothelial Carcinoma Market now

PARP Inhibitors in Urothelial Carcinoma

Mar 02, 2022

PARP inhibitors in Urothelial carcinoma (UC): Hit or miss?

Renal Cell Carcinoma Highlights- ASCO

Feb 25, 2022

ASCO GU 2022: Renal Cell Carcinoma Highlights

Bladder Cancer Highlights ASCO

Feb 25, 2022

Seagen/Astellas plans to expand their Antibody Drug Conjugate (ADC), Padcev in additional bladder cancer settings?

Chimeric antigen receptor T cell (CART) Treatment

Feb 24, 2022

With early-stage data, Chimeric antigen receptor T cell (CART) finding its way towards entering Prostate and Kidney Cancer market

Arvinas’s mCRPC ASCO

Feb 24, 2022

Early but strong clinical data of Arvinas’s ARV-110 in Men with mCRPC that support a potential path to accelerated approval

ASCO GU 2022

Feb 21, 2022

PARP inhibitors making inroads towards the first line metastatic Castrate-resistant prostate cancer (CRPC) market soon?

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper